SAGE Therapeutics (SAGE) Misses Q3 EPS by 21c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Sage Therapeutics Announces Third Quarter 2018 Financial Results and Highlights Pipeline and Business Progress
November 6, 2018 6:30 AM ESTFDA Advisory Committee Meeting outcome supports approval of ZULRESSO (brexanolone) injection as the first medicine specifically indicated for the treatment of postpartum depression (PPD)
Continuing to execute commercial strategy for ZULRESSO in PPD ahead of PDUFA target date of December 19, 2018 and readiness for planned U.S. launch in late March
Completion of enrollment in Phase 3 clinical trial of SAGE-217 in PPD top-line results expected in January 2019
Expansion of depression franchise with initiation of Phase 2 clinical trial of SAGE-217 in bipolar depression and multiple near-term trial initiations... More
